Nxera Pharma’s Daridorexant Delivers Phase 3 Insomnia Win
Nxera Pharma has reported encouraging top-line results from a phase 3 clinical trial of its insomnia treatment, daridorexant, in South Korea – an update that the company says clears a major hurdle on the road to a planned marketing submission in early 2026.
The late-stage study evaluated a 50 mg dose of daridorexant in both adult and elderly patients living with insomnia.
According to Nxera, the trial achieved what regulators and clinicians look for most at this stage: it met all primary and secondary endpoints, demonstrating statistically significant improvements versus placebo across multiple patient-reported sleep measures.
Clear gains across key sleep measures
In its announcement, Nxera said participants receiving daridorexant experienced meaningful improvements in subjective total sleep time, subjective latency to sleep onset, and subjective wake after sleep onset when compared with placebo.
In simple terms, patients reported sleeping longer, falling asleep faster, and spending less time awake during the night – three metrics that, collectively, speak to the everyday burden insomnia places on quality of life.
Importantly, the company also noted that the incidence of adverse events was similar across the daridorexant and placebo groups, supporting a safety profile that appears consistent within the context of this study population and setting.
A medicine already on the market – just not yet in South Korea
While the South Korean programme represents a fresh step forward for Nxera, daridorexant is not a newcomer globally. The drug is already approved and marketed in Japan under the brand name Quviviq, via a commercialisation agreement between Nxera and Shionogi.
Elsewhere, Quviviq is marketed by Idorsia in the United States, Canada, and several European countries, and by Simcere in China and Hong Kong.
Nxera’s latest results, therefore, are less about proving the medicine’s place in insomnia treatment worldwide, and more about building the evidence package needed to expand access into a market with significant unmet need.
The scale of insomnia in South Korea
Insomnia remains a widespread condition in South Korea, affecting an estimated 15–25% of adults – equating to roughly 6.5–11 million people.
Nxera framed the new data as a meaningful step towards expanding treatment options for this sizeable patient population, particularly given the condition’s well-documented impact on daily functioning, wellbeing, and productivity.
Company leadership points to 2026 and beyond
Commenting on the update, the President and Representative Director of Nxera Pharma Korea emphasised that insomnia is highly prevalent in South Korea and represents a serious health condition that can significantly affect patients’ daily lives.
They said the company is “very encouraged” by the positive phase 3 results, describing them as a critical milestone as Nxera prepares to submit a marketing authorisation application in the first quarter of 2026.
The executive added that the progress brings South Korean patients “one step closer” to gaining access to an important new treatment option. With Quviviq already available in the United States, Europe and Japan, Nxera said it is committed to working towards making the medicine available to patients in South Korea as quickly as possible.
Looking further ahead, Nxera expects regulatory approval in South Korea in the first quarter of 2027, positioning the programme as a near-term growth opportunity with a clearly defined timeline.
Conclusion
Taken together, Nxera Pharma’s phase 3 top-line results for daridorexant in South Korea mark a pivotal development: a 50 mg dose delivering significant placebo-adjusted improvements across multiple subjective sleep outcomes, alongside comparable adverse-event rates between treatment and placebo groups.
With Quviviq already established in major global markets through partnerships with Shionogi, Idorsia and Simcere, Nxera is now targeting South Korea – where millions are affected by insomnia – with a planned filing in Q1 2026 and an anticipated approval decision in Q1 2027.
If the momentum continues, the latest data may soon translate into a new, widely accessible option for patients whose nights – and days – are disrupted by chronic sleeplessness.
News Credits: Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
Things you may also like:
- Gosh! Serves Up Falafel “Food to Go” as Fibre Fever Takes Hold
- FDA Grants Priority Review to argenx’s VYVGART
- MHRA Clears GSK’s Nucala for Eosinophilic COPD